Genmab A/S
Genmab A/S
1,63 %
1 373,00 DKK
22,00
Kurs
1 373,00
Hög
1 376,00
Förändring
1,63 %
Låg
1 354,00
Uppdaterad
2019-08-19
Öppen
1 355,00
Factsheet for Genmab A/S
Company Profile
Description
Genmab is a cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and its promising first-in-class multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
Key Stats
Website: http://www.genmab.com
Headquarter country: Denmark
Employees: 157
Market Cap (at close 16-08-2019): DKK 88B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 46,50 54,90 97,30 125,70 69,00
Forward Price/Earnings 32,40 30,70
Price/Free Cash Flow 113,60 54,60 113,20 8 741,80 618,60
Return on Assets 19,50 18,60 26,00 22,60 13,10
Return on Equity 20,60 19,90 28,60 27,70 22,40
Return on Invested Capital 19,80 19,20 27,80 26,30 19,80
Dividend


Dividend/Share:
Ex. Dividend Date:0001-01-01
Trailing Dividend Yield:
Payout Ratio:0,00
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 3 025,14 2 365,44 1 816,12 1 133,04 850,39
Gross Profit
Gross Margin %
Operating Expenses 2018 2017 2016 2015 2014
EBITDA 1 700,00 1 136,00 1 171,00 789,00 314,00
Net income 1 472,00 1 104,00 1 187,00 764,00 301,00
Basic Earnings Per Share 24,03 18,14 19,83 13,05 5,35
Operating Income 1,38 1,34 1,05 0,73 0,27
Operating Margin % 45,63% 56,83% 57,97% 64,46% 31,18%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow 1 015,00 1 589,00 328,00 311,00 133,00
Capital Expenditures -477,00 -89,00 -33,00 -135,00 -75,00
Free Cash Flow 537,00 1 500,00 295,00 176,00 57,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 7 433,03 6 059,43 4 897,64 3 667,89 2 766,35 1 692,98
Long Term Assets 1 027,97 543,52 340,60 234,66 100,33 38,54
Total Assets 8 461,00 6 602,94 5 238,24 3 902,55 2 866,68 1 731,53
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 443,35 327,12 411,54 414,40 655,97 907,50
Long Term Liabilities 3,63 0,00 1,43
Total Liabilities 330,75 411,54 415,83
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings -197,46 -1 854,73 -3 106,11 -4 228,28 -5 028,36 -5 357,37
Treasury Stock
Total Stockholder Equity 8 014,36 6 272,19 4 826,70 3 486,72 2 032,94 659,52
Net Tangible Assets 7 544,00 6 147,80 4 644,80 3 294,08 1 970,41 656,98